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Adenosine A2A receptor (A2AR) antagonists have emerged as complementary non-
dopaminergic drugs to alleviate Parkinson’s disease (PD) symptomatology. Here, we
characterize a novel non-xhantine non-furan A2AR antagonist, PBF509, as a potential
pro-dopaminergic drug for PD management. First, PBF509 was shown to be a
highly potent ligand at the human A2AR, since it antagonized A2AR agonist-mediated
cAMP accumulation and impedance responses with KB values of 72.8 ± 17.4 and
8.2 ± 4.2 nM, respectively. Notably, these results validated our new A2AR-based
label-free assay as a robust and sensitive approach to characterize A2AR ligands.
Next, we evaluated the efficacy of PBF509 reversing motor impairments in several
rat models of movement disorders, including catalepsy, tremor, and hemiparkinsonism.
Thus, PBF509 (orally) antagonized haloperidol-mediated catalepsy, reduced pilocarpine-
induced tremulous jaw movements and potentiated the number of contralateral rotations
induced by L-3,4-dihydroxyphenylalanine (L-DOPA) in unilaterally 6-OHDA-lesioned rats.
Moreover, PBF509 (3 mg/kg) inhibited L-DOPA-induced dyskinesia (LID), showing
not only its efficacy on reversing parkinsonian motor impairments but also acting as
antidyskinetic agent. Overall, here we describe a new orally selective A2AR antagonist
with potential utility for PD treatment, and for some of the side effects associated to the
current pharmacotherapy (i.e., dyskinesia).
Keywords: PBF509, Parkinson’s disease, adenosine A2A receptor, catalepsy, label-free, tremor,
hemiparkinsonism, antagonist
INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative condition affecting around 1% of the population
over the age of 65 (Meissner et al., 2011). PD is characterized by bradykinesia, tremor,
and rigidity, which are secondary to the loss of dopamine neurons in the substantia nigra
(Poewe and Mahlknecht, 2009). The main therapeutic approach consists of administrating L-3,4-
dihydroxyphenylalanine (L-DOPA) or dopamine receptor agonists, thus recovering the functioning
of dopaminergic transmission (Poewe, 2009). However, a number of adverse effects appear upon the
long consumption of dopamine-like based drugs (Huot et al., 2013). From these, dyskinesia is the
most reported one, since, in most cases, it critically impedes the normal life of patients. Rotation
of dopamine-like based drugs is a normal strategy to diminish the appearance of these secondary
effects, but it seems clear that there is a need in PD clinics for searching novel agents that may
improve the management of the pathology (Schapira et al., 2006).
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From the new drugs developed not only to improve the clinical
features of classical drugs but also to alleviate their undesired side
effects, adenosine A2A receptor (A2AR) antagonists appear to be
the most promising ones. Interestingly, A2ARs are expressed in
GABAergic enkephalinergic neurons together with dopamine D2
receptors (D2R), which are the main target of PD drugs (Gerfen
et al., 1990). In addition, it has been largely studied the presence
of reciprocal functional interactions between both receptors, a
phenomenon that has been postulated to permit a fine-tuning
modulation of the basal ganglia functioning (for review see
Ferre et al., 2004). Furthermore, it was recently demonstrated
that both receptors form receptor complexes (i.e., oligomers),
in which a direct receptor-receptor interaction may drive the
functional interplay between A2AR and D2R (Fernández-Dueñas
et al., 2015). Nevertheless, apart from the plausible pre- and
post-synaptic mechanism mediating its effects (Schiffmann et al.,
2007), it has been clearly shown that A2AR antagonists show
an antiparkinsonian efficacy, and that they may also be used to
lessen undesired side effects of dopaminergic-like based drugs.
In such way, the obtained pre-clinical information points to the
use of A2AR antagonists as valuable agents for: (i) providing
motor benefits by themselves, (ii) potentiating the benefit of
dopamine agonists, or (iii) preventing the development of
dopamine-like drugs induced dyskinesias (for review see Hauser
and Schwarzschild, 2005; Jenner et al., 2009). In line with this,
randomized clinical studies have been performed to assess the
efficacy of these new A2AR-based drugs (for review see Vallano
et al., 2011). Indeed, an A2AR antagonist (i.e., istradefylline)
(Jenner, 2005) has been licensed in Japan (Nouriast R©) as an
adjuvant to L-DOPA treatment in order to reduce off-times
produced by the dopaminergic drug (Mizuno et al., 2010; Kondo
and Mizuno, 2015; Müller, 2015).
The development of new A2AR antagonists is consequently
a main objective in PD therapeutics, since they may
represent alternative or complementary drugs to deal with
the symptomatology associated with the pathology. Importantly,
it is crucial the information gained in pre-clinical studies, which
may permit to properly screen the better candidates to be tested
in randomized clinical studies. However, finding the optimal
animal model is not a simple task, and it is usually mandatory to
demonstrate the activity of any new drug in a variety of them.
Here, we describe the effectiveness of PBF509, a novel selective
and potent A2AR antagonist, in several rat animal models of
movement impairment: (i) the pilocarpine-induced tremulous
jaw movement (TJM), (ii) the hemiparkinsonian animal model,
and (iii) the L-DOPA induced dyskinesia (LID). Importantly,
we show the activity of this new antiparkinsonian drug in
comparison with other well-known A2AR-based agents, aiming
to prompt its future use in randomized clinical trials.
MATERIALS AND METHODS
Drugs
PBF509 (Mediavilla-Varela et al., 2017), synthesized by
PaloBiofarma, was dissolved in 0.5% methylcellulose for
oral administration. All other compounds were obtained from
external sources: 6-hydroxydopamine (6-OHDA), benserazide,
pilocarpine, haloperidol (Sigma-Aldrich, St. Louis, MO,
United States), 3,4-Dihydroxy-L-phenylalanine (L-DOPA;
Abcam Biochemicals, Cambridge, United Kingdom), CGS21680,
SCH442416, (Tocris Bioscience, Ellisville, MO, United States).
Antibodies
The primary antibodies used were rabbit anti-TH polyclonal
antibody (Millipore, Temecula, CA, United States), mouse
anti-A2AR monoclonal antibody (Millipore) and rabbit anti-
α-actinin polyclonal antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, United States). The secondary antibodies
were horseradish peroxidase (HRP)-conjugated goat anti-rabbit
and goat anti-mouse IgG (Pierce Biotechnology, Rockford,
IL, United States), and Cy2-conjugated donkey anti-rabbit
and Cy2-conjugated donkey anti-mouse antibodies (Jackson
ImmunoResearch Laboratories).
cAMP Accumulation Inhibition Assay
cAMP accumulation was measured using the LANCE Ultra
cAMP kit (PerkinElmer, Waltham, MA, United States) (Taura
et al., 2016). In brief, HEK-293 cells permanently expressing
the A2ARSNAP construct (Fernández-Dueñas et al., 2015) were
incubated in the absence or presence of increasing concentrations
of SCH442416 or PBF509 before stimulating the cells with
CGS21260 (∼EC80) for 30 min at 22◦C with adenosine
deaminase (0.5 U/ml; Roche). Eu-cAMP tracer and ULightTM-
anti-cAMP reagents were prepared and added to the sample
according to the LANCE R© Ultra cAMP Kit instruction manual.
384-wells plate was incubated 1 h at 22◦C in the dark and
was then read on a POLARstar microplate reader (BMG
LABTECH, Durham, NC, United States). Measurement at
620 and 665 nm were used to detect the TR-FRET signal
and the concomitant cAMP levels were calculated following
manufacturer’s instructions. Data were fitted by non-linear
regression using GraphPad Prism 5 (GraphPad Software).
Concentration-response curves were carried out by assaying
different ligand (i.e., PBF509 and SCH442416) concentrations
ranging between 10 nM to 30 µM. Data was expressed as KB by
following the formula reported by Leff and Dougall (1993):
KB = IC50/[2+ ([A]/[A50])n](1/n)−1
Where IC50 is the concentration of compound that inhibits
CGS21680 effect by a 50%; [A] is the concentration of CGS21680
employed in the assay, [A50] is the CGS21680 EC50 value and n is
the Hill slope of the curve.
Cellular Impedance Assay Label-Free
The xCELLigence RTCA system (Roche) was employed to
measure changes in cellular impedance correlating with
cell spreading and tightness, thus being widely accepted as
morphological and functional biosensor of cell status (Xu et al.,
2016). Accordingly, we assessed the impact of A2AR blockade in
cellular impedance (Solly et al., 2004; Stallaert et al., 2012; Hillger
et al., 2015). To this end, HEK-293 cells permanently expressing
the A2ARSNAP construct (Fernández-Dueñas et al., 2015) were
growth in Dulbecco’s modified Eagle’s medium (DMEM) (Sigma-
Aldrich) supplemented with 1 mM sodium pyruvate (Biowest,
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Nuaillé, France), 2 mM L-glutamine (Biowest), 100 U/mL
streptomycin (Biowest), 100 mg/mL penicillin (Biowest), and
1.5% (v/v) fetal bovine serum (Gibco) in presence of 0.5 U/ml
of adenosine deaminase. The 16-wells E-plates (Roche) were
used. Wells were coated with 50 µl fibronectin (10 µg/ml).
Plates were placed at 37◦C for 1 h. After removing coating
liquid, plates were washed three times with 100 µl Milli-Q-water
before use. The background index for each well was determined
with supplemented DMEM (90 µl) in the absence of cells.
Data from each well were normalized to the time point just
before compound addition using the RTCA software providing
the normalized cell index (NCI). Subsequently, cells (90 µl
re-suspended in supplemented DMEM were then plated at a cell
density of 10,000 cells/well and grown for 18 h in the RTCA SP
device station (Roche) at 37◦C and in an atmosphere of 5% CO2
before ligand (i.e., CGS21680) addition. For the concentration-
response inhibition of CGS21680-mediated effect the cells were
first incubated with the corresponding antagonist (i.e., PBF509
or SCH442416) for 1 h and then CGS21680 (∼EC80) was added.
Cell index values were obtained immediately following ligand
stimulation every 15 s for a total time of at least 100 min. For
data analysis, ligand (i.e., SCH442416 and PBF509) responses
were transformed to1NCI after subtracting baseline (i.e., vehicle
control) to correct for any ligand-independent effects. The1NCI
was then taken at 30 min after the agonist addition to build
the concentration-response curve. 1NCI were expressed in %
considering 1 µM of CGS21680 as the 100% and the vehicle as
the 0%.
Animals
Sprague-Dawley rats (Charles River Laboratories, L’Arbresle,
France) weighing 240–250 g were used. The University of
Barcelona Committee on Animal Use and Care approved the
protocol. Animals were housed and tested in compliance with
the guidelines provided by the Guide for the Care and Use
of Laboratory Animals (Clark et al., 1997) and following the
European Union directives (2010/63/EU). All efforts were made
to minimize animal suffering and the number of animals used.
Rats were housed in groups of three in standard cages with
ad libitum access to food and water and maintained under a
12 h dark/light cycle (starting at 7:30 AM), 22◦C temperature,
and 66% humidity (standard conditions). All animal model
observations were made between 9:00 AM and 1:00 PM.
Haloperidol-Induced Catalepsy
Rats (n = 10) were randomly assigned to treatment groups
and behavioral testing was performed blind to treatment. The
dopamine D2 receptor (D2R) antagonist, haloperidol (1 mg/kg,
s.c.) was administered to induce catalepsy. Thirty minutes
after the haloperidol administration, rats experienced a full
cataleptic response. At this time point, for each rat the state
of catalepsy was tested by gently placing their front limbs
over an 8-cm high horizontal bar. The intensity of catalepsy
was assessed by measuring the time the rats remain in this
position being completely immobile for a maximum of 120 s.
Only rats that remained cataleptic for the entire 120 s were
used for subsequent drug testing. After 30 min of the baseline
measurement vehicle (0.5% methylcellulose and 2% DMSO) or
PBF509 was administered orally via gavage (3, 10, or 30 mg/kg,
p.o.) and the catalepsy was then determined at 15, 30, and
60 min PBF509 administration. For each time point the number
of responding rats and the total cataleptic time for each animal
was determined.
Pilocarpine-Induced TJM
Rats were placed in the observation chamber (30 cm diameter and
40 cm high clear glass chamber with a mesh floor and elevated
40 cm from the bench) to habituate during 5 min before being
orally administered with vehicle (0.5% methylcellulose and 2%
DMSO) or the indicated A2AR antagonist (i.e., SCH442416 and
PBF509), followed (20 min) by pilocarpine (1 mg/kg; i.p.). Five
minutes after pilocarpine injection TJMs were counted for 1 h
(divided into six tests of 10 min each). TJMs were defined as
rapid vertical deflections of the lower jaw that resembled chewing
but were not directed at any particular stimulus (Salamone et al.,
1998). Each individual deflection of the jaw was recorded using
a mechanical hand counter by a trained observer, who was blind
to the experimental condition of the rat being observed (Gandía
et al., 2015).
Hemiparkinsonian Animal Model
Experimental hemiparkinsonism was induced in rats by
unilateral injection of 6-OHDA in the medial forebrain bundle
as previously described (Fernández-Dueñas et al., 2015).
Accordingly, rats were stereotaxically injected with 6-OHDA
(8 µg of 6-OHDA in 4 µl of saline solution containing 0.05%
ascorbic acid) at: AP (anterior-posterior) = −2.2 mm, ML
(medial-lateral) =−1.5 mm and DV (dorsal-ventral) =−7.8 mm
with respect to bregma (Paxinos and Watson, 2007). To
minimize damage to noradrenergic neurons, rats were pretreated
with desipramine hydrochloride (10 mg/kg, i.p.) 20 min
before surgery. Then, 3 weeks after the lesion the extent of
dopamine deafferentation was validated by assessing the rotating
behavioral response to L-DOPA administration. In brief, rats
were injected with L-DOPA (50 mg/kg, i.p.) in the presence of
benserazide hydrochloride (25 mg/kg, i.p.) and the number of
full contralateral turns recorded during a 2 h period. Dopamine
deafferentation was considered successful in those animals that
made at least 200 net contralateral rotations. Thereafter, animals
were housed during 3 weeks before used.
To test the effect of A2AR antagonists in the hemiparkinsonian
animal model compounds were orally administered in vehicle
(0.5% methylcellulose and 2% DMSO) 40 min before the
administration of benserazide (25 mg/kg; i.p.). Subsequently, L-
DOPA (4 mg/kg; i.p.) was delivered 20 min later and placed in
the rotametry chambers, as previously described (Hodgson et al.,
2009). The number of contralateral rotations was recorded during
a 2-h period.
LIDs and Abnormal Involuntary
Movements (AIMs) Rating
L-DOPA-induced dyskinesias were triggered to the
hemiparkinsonian rats (see above) by twice a day administration
Frontiers in Pharmacology | www.frontiersin.org 3 October 2018 | Volume 9 | Article 1200
fphar-09-01200 October 19, 2018 Time: 12:34 # 4
Núñez et al. PBF509, an Antiparkinsonian Agent
of L-DOPA (4 mg/kg, i.p.) plus benserazide hydrochloride
(15 mg/kg, i.p.) during 22 consecutive days. Subsequently, the
L-DOPA-induced AIMs were scored by a blinded experimenter
following a rat dyskinesia scale previously described (Winkler
et al., 2002). In brief, rats were injected with L-DOPA, placed
individually in transparent plastic cages and observed every
20 min during 220 min. Thus, three subtypes of AIMs were
monitored (i.e., axial, forelimb, and orolingual) and their
respective severity scored from 0 to 4 as previously described
(Winkler et al., 2002). Enhanced manifestations of otherwise
normal behaviors, such as rearing, sniffing, grooming, and
gnawing, were not included in the rating. Accurate AIM ratings
were subsequently performed on treatment days 1, 7, 14, and 22
during the chronic L-DOPA administration phase. We computed
integrated AIM scores for each animal and testing session using
the sum of all three AIM subtypes and expressed as the area
under the curve (AUC).
Gel Electrophoresis and Immunoblotting
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS/PAGE) was per-formed using 10% polyacrylamide gels.
Proteins were transferred to PVDF membranes using a semidry
transfer system and immunoblotted with the indicated antibody
and then HRP-conjugated rabbit antigoat (1:30,000) or goat
anti-rabbit IgG (1:30,000). The immunoreactive bands were
developed using a chemiluminescent detection kit (Pierce) and
the Amersham Imager 600 (GE Healthcare Europe GmbH,
Barcelona, Spain).
Immunohistochemistry
Rat brains were fixed and coronal sections (50–70 µm) obtained
as previously described (Taura et al., 2015). Slices were collected
in Walter’s Antifreezing solution (30% glycerol, 30% ethylene
glycol in PBS, pH 7.2) and kept at−20◦C until processing.
For immunohistochemistry, previously collected slices were
washed three times in PBS, permeabilized with 0.3% Triton X-
100 in PBS for 2 h and rinsed back three times more with
wash solution (0.05% Triton X-100 in PBS). The slices were then
incubated with blocking solution (10% NDS in wash solution;
Jackson ImmunoResearch Laboratories, Inc., West Grove, PA,
United States) for 2 h at R.T. and subsequently incubated with
rabbit anti-TH polyclonal antibody (1 µg/ml) and mouse anti-
A2AR monoclonal antibody (1 µg/ml) overnight at 4◦C. After
two rinses (10 min each) with 1% NDS in wash solution, sections
were incubated for 2 h at R.T. with either Cy2-conjugated donkey
anti-rabbit (1:200) or Cy2-conjugated donkey anti-mouse (1:200)
antibodies before being washed (10 min each) two times with
1% NDS in wash solution and two more times with PBS and
mounted on slides. Fluorescence images of whole brain coronal
sections were obtained using a SteREO Lumar.V12 fluorescence
stereoscope (Carl Zeiss MicroImaging GmbH, Oberkochen,
Germany).
Statistics
The number of samples (n) in each experimental condition is
indicated in figure legends. When two experimental conditions
were compared, statistical analysis was performed using an
unpaired t-test. Otherwise, statistical analysis was performed by
one-way analysis of variance (ANOVA) followed by Bonferroni
post hoc test. Statistical significance was set as P < 0.05.
RESULTS
Functional Activity of PBF509 at Human
Recombinant A2AR
PBF509 is a structurally novel non-xanthine and non-furan
A2AR antagonist. The affinity of PBF509 for all four human
adenosine receptors was recently reported by means of classical
radioligand competition binding assays using membrane extracts
from cells expressing A1R, A2AR, A2BR, and A3R (Mediavilla-
Varela et al., 2017). Thus, PBF509 bound A2AR with high affinity
(K i = 12± 0.2 nM) and showed 416-, 208-, and 83-fold selectivity
over the A3R, A1R, and A2BR, respectively (Mediavilla-Varela
et al., 2017).
In functional assays, PBF509 did not show any agonist efficacy
in HEK cells permanently expressing the human A2ARSNAP
(data not shown). However, PBF509 completely antagonized the
agonist-mediated cAMP accumulation in A2ARSNAP expressing
HEK cells (Figure 1), thus showing a KB value of 72.8± 17.4 nM
(Figure 1). Interestingly, while the PBF509 KB value was
significantly different [F(1,60) = 11.5, P < 0.005] from the one
found for a well characterized A2AR antagonist (Todde et al.,
2000), SCH442416 (KB = 28.8± 7.2 nM; Figure 1), it was within
the same range as previously described (Mediavilla-Varela et al.,
2017). Thus, these results suggested that PBF509 was equipotent
in blocking A2AR-mediated cAMP accumulation at the moderate
nanomolar range.
Next, we aimed to characterize the functional activity of
PBF509 using a label-free technology. To this end, the whole-cell
agonist-mediated impedance responses were monitored in the
presence or absence of PBF509 using a biosensor method. Once
FIGURE 1 | Inhibition of A2AR-mediated cAMP accumulation. Inhibition of the
CGS21680-mediated cAMP accumulation. A SCH442416 and PBF509
concentration-response inhibition curve of CGS21260-mediated cAMP was
assessed in HEK-293 cells permanently expressing the A2ARSNAP. Data are
representative of three separate experiments performed in duplicate.
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completed the optimization of the assay (see section “Materials
and Methods”), we first tested the CGS21680-mediated changes
in morphology (i.e., impedance) of A2ARSNAP expressing HEK
cells, which were recorded in real-time. Interestingly, addition
of CGS21680 resulted in an immediate and concentration-
dependent increase of impedance (Figure 2A). The EC50 found
for this CGS21680-mediated impedance change was of 127 ± 74
and 61 ± 31 nM, for measurements performed at 30 and
60 min, respectively (Figure 2B). As the potency value did
not significantly differ between the two time points measured
[F(1,21) = 1.256, P = 0.274], we assessed the ability of PBF509 to
block the CGS-induced impedance change at 30 min (Figure 2C).
Of note, while SCH442416 showed a KB value of 0.2 ± 0.07 nM,
PBF509 displayed a KB of 8.2 ± 4.2 nM (Figure 2C). Thus,
the PBF509 inhibitory potency of A2AR-mediated impedance
increase was within the low nanomolar range, following the
same tendency to that displayed by SCH442416. Overall, the two
functional assays used confirmed a lower potency of PBF509
vs. SCH442416 in blocking the A2AR-mediated signaling, which
FIGURE 2 | PBF509 blocks A2AR-mediated whole cell label-free responses.
(A) Representative example of the A2ARSNAP cells impedance signal in
response to CGS216980 (10 µM–100 pM) over the time. Cell lines were
stimulated with the A2AR selective agonist CGS21680 18 h after seeding
(10,000 cells/well) and the impedance signal recorded over 60 min as
described in materials and methods. (B) Concentration-response curves of
CGS21680 derived from the normalized cell index (NCI) shown in (A) within 30
or 60 min after agonist addition. EC50 values of CGS21680 were 127 ± 74
and 61 ± 31 nM at 30 and 60 min, respectively. (C) Inhibition of the
CGS21680-mediated impedance signal. Cell lines were pre-incubated for
60 min with increasing concentrations of SCH442416 and PBF509
(10 µM–100 pM) before stimulation with CGS21680 (500 nM).
Concentration-response curves of SCH442416 and PBF509 were derived
from 1NCI within 30 min after agonist addition. Data are representative of
three separate experiments performed in duplicate.
ranged from 2.5-fold in the cAMP assay and 40-fold in the label-
free approach. Importantly, the potency values derived from the
label-free assay provided a proof-of-principle that this biosensor




Once determined the potency and intrinsic activity of PBF509
we aimed to determine the pro-dopaminergic nature of this
compound in vivo. To this end, we evaluated the ability of
PBF509 to block D2R antagonist-mediated catalepsy. PBF509
dose-dependently attenuated the cataleptic effects of haloperidol
when administered 1 h after haloperidol injection (Figure 3).
Interestingly, the anticataleptic activity of PBF509 was observed
after 15 min of administration at all the doses tested (3, 10,
and 30 mg/kg) and lasted for at least 1 h post-administration
of PBF509 (Figure 3). These results are in good agreement with
the early description of anticataleptic activity of A2AR antagonists
(Kanda et al., 1994).
PBF509 Attenuates Pilocarpine-Induced
Tremulous Jaw Movements
The adenosinergic system has emerged as a potential target
for the treatment of parkinsonian symptoms, including tremor
(Schwarzschild et al., 2006). Indeed, A2AR antagonists have been
shown to be efficacious to reduce drug-induced tremor (Simola
et al., 2004). Accordingly, we aimed to test whether PBF509 was
able to reduce pilocarpine-induced tremulous jaw movements
(TJMs), an animal model of parkinsonian tremor previously
FIGURE 3 | PBF509 reverses haloperidol-induced catalepsy. Rats were
pretreated with haloperidol (1.0 mg/kg, s.c.) and 1 h later the selected
cataleptic animals were orally administered with either vehicle or PBF509 (3,
10, and 30 mg/kg, p.o.). The time spent in a cataleptic position was
measured after 15, 30, and 60 min after PBF509 administration. The data
represent the mean time spent cataleptic ± SEM over a period of 120 s
measurement (n = 3–8 animals/group). The cataleptic behavior was calculated
and compared within groups by a two-way ANOVA followed by Bonferroni’s
post hoc test. Group differences were calculated by a non-parametric Kruskal
Wallis ANOVA followed by a Dunn’s post-test as Gaussian distribution was
missing. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. The alpha-error level was set
to 0.05.
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used (Salamone et al., 2013; Gandía et al., 2015). Interestingly,
PBF509 dose-dependently attenuated pilocarpine-induced TJMs,
being effective at the lowest dose tested (0.3 mg/kg; Figure 4).
It is important to mention here that PBF509 showed similar
potency to SCH442416 in reducing TJMs (Figure 4). Thus, these
results suggested that parkinsonian rest tremor, which is relatively
resistant to dopamine-replacement therapy, might be potentially
targeted by PBF509.
Effect of PBF509 on L-DOPA-Induced
Turning Behavior
Next, we aimed to evaluate the antiparkinsonian effectiveness
of PBF509 using the unilateral 6-OHDA lesioned rat, a classic
and widespread toxin-based animal model of experimental
parkinsonism (Schwarting and Huston, 1996). To this end,
we first validated the extent of the 6-OHDA lesion in our
hemiparkinsonian animal model by monitoring the striatal
tyrosine hydroxylase (TH) density, a marker of dopaminergic
innervation. As expected, a significant reduction (∼75%)
of TH density in the lesioned striatum (L) was observed
by immunoblot (Figures 5A,B) and immunohistochemistry
(Figure 5C), thus corroborating the 6-OHDA-mediated loss
of striatal dopaminergic innervation. Interestingly, when the
A2AR immunoreactivity was assessed not significant differences
(P = 0.193) between the healthy (R) and the lesioned (L) striatum
were observed (Figure 5).
In the hemiparkinsonian animal model, an asymmetry
in motor behavior is produced upon administration of
dopaminergic agents (i.e., L-DOPA), a consequence of the
unilateral dopamine depletion in the nigrostriatal pathway (Duty
FIGURE 4 | PBF509 attenuates pilocarpine-induced tremulous jaw
movements. Effect of different doses of SCH442416 and PBF509 on
pilocarpine-induced tremulous jaw movements. The number of jaw
movements were recorded during 1 h in rats orally administered with vehicle
(Veh), SCH442416 or PBF509 (0.3–7.5 mg/kg) before (20 min) pilocarpine
administration (1 mg/kg, i.p.). Values correspond to the mean ± SEM of 6–7
animals for each condition and expressed as percentage of the TJMs
observed in the vehicle. TJMs were absent in animals no treated with
pilocarpine. The asterisks denote data significantly different from the vehicle
condition: ∗P < 0.05 and ∗∗∗P < 0.001, one-way ANOVA with a Bonferroni’s
post hoc test.
FIGURE 5 | Immunoreactivity of A2AR in the striatum of 6-OHDA-lesioned
rats. (A) Immunoblot analysis of TH and A2AR density in striatal membranes
from control (R) and 6-OHDA lesioned (L) striatal hemisphere. Striatal
membranes were analyzed by SDS–PAGE and immunoblotted using a rabbit
anti-TH polyclonal antibody (1 µg/ml), a mouse anti-A2AR monoclonal
antibody (1 µg/ml) and a rabbit anti-α-actinin polyclonal antibody (1 µg/ml).
A HRP-conjugated anti-rabbit or anti-mouse IgG (1/30,000) was used as a
secondary antibody. The immunoreactive bands were visualized by
chemiluminescence. Load control used for quantitating was α-actinin.
A representative blot for three different lesioned animals is shown.
(B) Quantification of TH and A2AR density in striatal membranes from control
(R) and 6-OHDA lesioned (L) striatal hemisphere. The immunoreactive bands
corresponding to TH and A2AR in each striatal hemisphere were normalized by
α-actinin immunoreactivity. Data are expressed as percentage of the control
(R) TH or A2AR density ± SEM of three independent experiments. Asterisks
indicate data significantly different from the control condition: ∗∗∗P < 0.0001
by Student’s t-test. NS: not statistically significant. (C) Photomicrographs
showing, by means of TH staining (upper panel), the loss of dopaminergic
innervation in the lesioned striatum (L) compared to the non-lesioned (R)
striatum, and the density of A2AR (lower panel) in 6-OHDA-lesioned rat brain
coronal slices (see section “Materials and Methods”).
and Jenner, 2011). Accordingly, pro-dopaminergic compounds
can
promote contralateral rotations of lesioned animals upon
submaximal L-DOPA dosing (4 mg/kg, for our hemiparkinsonian
rats). The administration of A2AR antagonists, either SCH420814
(preladenant) or PBF509, up to 3 mg/kg, to 6-OHDA lesioned
rats did not result in asymmetric turning behavior (Figure 6).
However, both compounds dose-dependently induced a
contralateral turning behavior when administrated before the
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FIGURE 6 | PBF509-mediated potentiation of L-DOPA-induced contralateral
rotations in 6-OHDA-lesioned rats. The number of contralateral rotations in
6-OHDA-lesioned rats orally administered with vehicle (Veh) or SCH420814
and PBF509 (0.3 and 3 mg/kg) in the absence or presence of L-DOPA
(4 mg/kg) was monitored during a 2 h period. Values correspond to the
mean ± SEM of 10–15 animals for each condition. The asterisks denote data
significantly different from the vehicle condition: ∗P < 0.05 and ∗∗∗P < 0.001,
one-way ANOVA with a Bonferroni’s post hoc test.
subthreshold dose of L-DOPA (Figure 6). Overall, PBF509
was able to enhance the effects of L-DOPA with a minimum
efficacious dose (MED) of 3 mg/kg p.o., and equal in efficacy to
SCH420814 at this dose.
PBF509 Reduces L-DOPA-Induced
Dyskinesia (LID)
Chronic L-DOPA use in PD is often associated with the
development of LIDs. Accordingly, alleviating this adverse
side effect related to PD therapy constitutes a therapeutic
challenge. Interestingly, a relationship between A2AR and LIDs
has been established, thus an increased striatal A2AR density
has been reported in experimental animal models of LID
(Zeng et al., 2000) and in PD patients with dyskinesia (Calon
et al., 2004; Ramlackhansingh et al., 2011). Here, we aimed
to assess the potential antidyskinetic activity of PBF509. To
this end, we induced LIDs to our 6-OHDA lesioned rats by
chronic L-DOPA administration and the emergence of abnormal
involuntary movements (AIMs) over time was monitored.
Indeed, a time L-DOPA-dependent AIMs manifestation was
observed (Figure 7A). Thus, AIM severity increased during
the first 40 min post-injection and remained significantly
(P < 0.01) elevated for an additional 40 min in one-week L-
DOPA administrated animals (Figure 7A, Day 7). A follow up
of these animals over time showed that after 2 weeks of L-
DOPA administration the AIMs remained robustly (P < 0.001)
elevated during 80 min and after 3 weeks the animals
showed a longer and sustained LIDs incidence (Figure 7A).
Interestingly, the observed time-course in our LID animal model
resembled the so called peak-dose dyskinesia in PD (Fahn,
FIGURE 7 | Effect of PBF509 in LID rats. (A) L-DOPA induced-motor side
effects (i.e., LIDs) development upon chronic (22 days) L-DOPA (4 mg/kg)
administration. AIM score was measured during a 220-min on days 1, 7, 14,
and 22 after the corresponding daily L-DOPA administration. The total AIMs
score over 200 min was quantified and expressed as area under the curve
(AUC) ± SEM (n = 8). ∗∗P < 0.01 and ∗∗∗P < 0.001 one-way ANOVA with
Dunnett’s post hoc test when compared to day 1. (B) Immunoreactivity of
A2AR in the striatum of dyskinetic rats. TH and A2AR density in striatal
membranes from control (R) and 6-OHDA lesioned (L) striatal hemisphere of
LID animals was analyzed by immunoblot and quantified as described in
Figure 4. Data are expressed as percentage of the control (R) TH or A2AR
density ± SEM of three independent experiments. Asterisks indicate data
significantly different from the control condition: ∗∗∗P < 0.001, ∗P < 0.05 by
Student’s t-test. (C) LID attenuation in chronic (22 days) L-DOPA (4 mg/kg)
administered rats following administration of A2AR antagonists. The total AIM
score (area under the curve, AUC) obtained over 220 min following
co-administration of L-DOPA (4 mg/kg) plus vehicle (Veh), SCH420814
(3 mg/kg) and PBF509 (3 mg/kg) are presented as mean score ± SEM
(n = 6). The asterisks denote data significantly different from the vehicle
condition: ∗∗∗P < 0.001, one-way ANOVA with a Bonferroni’s post hoc test.
NS: not statistically significant.
2000). Subsequently, we next demonstrated that chronic L-DOPA
treatment of hemiparkinsonian rats prompted a significant
increase (15 ± 2%, P < 0.05) of striatal A2AR density in
the lesioned hemisphere (Figure 7B), in agreement to that
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described previously. Then, under these experimental conditions,
we assessed the antidyskinetic activity of PBF509. The drug
was used at the antiparkinsonian MED (3 mg/kg, p.o.), and it
showed an antidyskinetic efficacy similar to that observed for
SCH420814 (Figure 7C). Overall, while PBF509 showed a robust
antiparkinsonian activity it also displayed antidyskinetic efficacy.
DISCUSSION
Dopamine augmentation constitutes the first line therapy in PD.
Hence, L-DOPA or direct dopamine agonists (i.e., ropinirole,
pramipexole, apomorphine) are regular drugs for PD clinical
management (Poewe and Mahlknecht, 2009). Interestingly,
while dopamine-targeted therapies allow proper management
of PD, associated motor disturbances have considerable side
effects both after acute and chronic regimes (i.e., hallucinations,
constipation, nausea, somnolence, on-off effects, dyskinesia)
(Eggert et al., 2008). In addition, these therapies usually display
an efficacy decline along the disease development and do
not address other disease disturbances frequently associated to
PD (i.e., mood, postural instability, or cognitive disturbances).
Accordingly, alternative approaches modulating dopaminergic
neurotransmission in PD have emerged as potential alternatives
to manage PD therapy-associated side effects (Fox et al.,
2008). Indeed, A2AR blockade has been demonstrated to be
effective in both preclinical and clinical PD studies (Vallano
et al., 2011; Pinna, 2014). Interestingly, it has been proposed
that the mechanism behind the pro-dopaminergic activity of
A2AR antagonists may rely in part to the existing functional
and molecular interaction (i.e., heteromerization) of A2AR and
D2R within the striatum (Ferre et al., 2004; Fernández-Dueñas
et al., 2015). Thus, a mutual trans-inhibition between these
two receptors has been largely described (Ferre et al., 2008).
In addition to this postsynaptic site of action, striatal A2AR
show also presynaptic expression on glutamatergic terminals of
the cortico-limbic-striatal and thalamo-striatal pathways forming
heteromeric complexes with adenosine A1 receptors (Ciruela
et al., 2006) and driving striatal circuits controlling motor
function independently of dopaminergic signaling (Schiffmann
et al., 2007).
The initial work identifying novel A2AR antagonists focused
on purine and xanthine derivatives, principally built from
adenosine and the naturally occurring antagonist caffeine. In
parallel, further effort was set on non-xanthine furan-based
derivatives, such as triazolotriazines and triazolopyrimidines
(e.g., ZM241385, BIIB014 and SCH420814). However, regardless
of the good affinity and selectivity shown, these A2AR antagonists
have, in general, high molecular weight, thus they are complex
and difficult to synthesize. In addition, they display poor
water solubility, and their furan group precludes replacement
by empirical medicinal chemistry. Here, we characterize the
functional activity of PBF509, a new non-xanthine and non-
furan competitive antagonist with high affinity and selectivity
for the A2AR (Mediavilla-Varela et al., 2017), through a highly
sensitive TR-FRET-based cAMP accumulation assay in A2AR
expressing cells. Interestingly, to further characterize the its
activity we implemented a label-free xCELLigence assay based
on the real-time impedance recording of A2AR expressing
cells. Thus, upon similar physiological conditions of the
xCELLigence assay (i.e., regular cell culture growing), PBF509
displayed comparable potency in blocking the A2AR-mediated
signaling when compared to the cAMP assay. Noteworthy,
apart from revealing PBF509 antiparkinsonian efficacy, our
work led to the description of a whole-cell label-free approach
for investigating A2AR-mediated drug responses in A2ARSNAP
expressing HEK cells, which may allow cellular assays with
minimal modifications and increased sensitivity over traditional
label-based methodologies.
PBF509 was effective in reducing catalepsy induced by
haloperidol, a D2R antagonist. Interestingly, anticataleptic
properties have been classically used to predict clinical efficacy
for antiparkinsonian drugs (i.e., pramipexole) (Maj et al., 1997).
Thus, our results suggested that PBF509-induced A2AR blockade
provided a counterbalance to the loss of D2R-mediated effects
in the basal ganglia indirect pathway, as previously described
for other A2AR antagonists (Shiozaki et al., 1999). Moreover,
PBF509-mediated A2AR blockade reduced pilocarpine-induced
tremulous jaw movements and potentiated L-DOPA-induced
contralateral rotations in unilaterally 6-OHDA-lesioned rats,
which is consistent with previous findings using other A2AR
antagonists (Hodgson et al., 2009). In addition, PBF509 showed
antidyskinetic efficacy in the LID animal model, which correlated
well with the increased striatal A2AR expression. Overall, our
results support the potential usefulness of PBF509 in PD
management, including its ability to reduce dyskinesia when used
in combination with L-DOPA in PD treatment.
A number of A2AR antagonists have been proposed as
antiparkinsonian agents and tested in preclinical PD animal
models. For instance, ST-1535 (Rose et al., 2006; Tronci
et al., 2007) and related metabolites (i.e., ST3932 and ST4206)
(Stasi et al., 2015), and JNJ40255293 (Atack et al., 2014),
which are based on the purine adenosine. Also, the xanthine-
based compounds, as KW6002 (istradefylline) (LeWitt et al.,
2008) and the non-xanthine SCH58261 (Simola et al., 2004),
SCH420814 (preladenant) (Hodgson et al., 2009), and BIIB014
(vipadenant) (Gillespie et al., 2009), amongst others. However,
among the A2AR antagonists undergoing clinical trials (Vallano
et al., 2011; Pinna, 2014), only the xanthine istradefylline has
been approved for manufacturing and marketing (in Japan,
2013), thus becoming the world’s first antiparkinsonian agent
of a first-in-class A2AR antagonist. In clinical trials, Nouriast R©
(istradefylline) improved wearing-off phenomena and was well
tolerated by PD patients treated with L-DOPA. On the other
hand, the non-xanthine preladenant did not prove itself to be
more effective than placebo during Phase-III trials, and was
discontinued in 2013, as it was vipadenant. Similarly, despite
the robust preclinical pharmacology and good pharmacokinetic
properties of JNJ40255293, its development was halted due to
preclinical toxicity. Here, we have described a selective non-
xanthine and non-furan A2AR antagonist with efficacy in rat
models of movement disorders and without preclinical toxicity.
Interestingly, in a double-blind, placebo-controlled, Phase-I
clinical trial (NCT01691924) of single ascending oral doses in
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32 healthy male volunteers, PBF509 showed safety, tolerability
and feasibility. Thus, the compound is currently in prospective
Phase-II clinical trials for PD.
In summary, PBF509 demonstrated remarkable potential in
experimental animal models of movement disorders, including
PD and LID, thus becoming an excellent candidate for clinical
A2AR-based treatment of PD motor symptoms. In addition, the
ability of PBF509 to alleviate non-motor symptoms associated
with PD (i.e., memory and mood impairments and sleep
disturbances) will deserve future clinical attention.
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